Comparison of strategies to overcome the hypertensive effect of combretastatin-A4 phosphate in a rat model

被引：0
|
作者：
Honess, DJ
Hylands, F
Chaplin, DJ
Tozer, GM
机构：
[1] Oxigene Inc, Watertown, MA 02472 USA
[2] Mt Vernon Hosp, Gray Canc Inst, Tumor Microcirculat Grp, Northwood HA6 2JR, Middx, England
来源：
BRITISH JOURNAL OF CANCER | 2002年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S118 / S119
页数：2
相关论文
共 50 条
  • [31] The greater antitumour effect of combretastatin A1 phosphate (CA1P, OXI4503) compared to combretastatin A4 phosphate (CA4P) may be explained by differences in pharmacokinetics (PK) and metabolism.
    Kirwan, G
    Loadman, PM
    Swaine, DJ
    Bibby, MC
    Pettit, GR
    Lippert, JW
    Shnyder, SD
    Cooper, PA
    Anthoney, DA
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6150S - 6150S
  • [32] QUANTITATIVE EVALUATION OF COMBRETASTATIN A4 PHOSPHATE EARLY EFFICACY IN A TUMOR MODEL WITH DYNAMIC CONTRAST-ENHANCED ULTRASOUND
    Zhang, Pingyu
    Chen, Yihan
    Liu, JinFeng
    Yang, Yali
    Lv, Qing
    Wang, Jing
    Zhang, Li
    Xie, Mingxing
    ULTRASOUND IN MEDICINE AND BIOLOGY, 2018, 44 (04): : 840 - 852
  • [33] The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours
    Chen, Gang
    Horsman, Michael R.
    Pedersen, Michael
    Pang, Qi
    Stodkilde-Jorgensen, Hans
    ACTA ONCOLOGICA, 2008, 47 (06) : 1071 - 1076
  • [34] Oxi4503, a novel vascular targeting agent: Effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate
    Hua, JY
    Sheng, YZ
    Pinney, KG
    Garner, CM
    Kane, RR
    Prezioso, JA
    Pettit, GR
    Chaplin, DJ
    Edvardsen, K
    ANTICANCER RESEARCH, 2003, 23 (2B) : 1433 - 1440
  • [35] Vascular disrupting effect of combretastatin A-4 phosphate with inhibition of vascular endothelial cadherin in canine osteosarcoma-xenografted mice
    Izumi, Yusuke
    Takagi, Satoshi
    RESEARCH IN VETERINARY SCIENCE, 2019, 122 : 1 - 6
  • [36] Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model
    Malcontenti-Wilson, C
    Muralidharan, V
    Skinner, S
    Christophi, C
    Sherris, D
    O'Brien, PE
    CLINICAL CANCER RESEARCH, 2001, 7 (04) : 1052 - 1060
  • [37] Combretastatin A-4 Phosphate (CA4P) is effective for the treatment of functional pancreatic neuroendocrine tumors (PNETs) in a transgenic mouse model.
    Yuan, Ziqiang
    Zaphiros, Nikolas
    Adem, Asha
    Etienne, Norvilia
    Balkissoon, Jai
    Chaplin, Dal
    Libutti, Steven K.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [38] Vascular targeting of solid tumours:: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas
    Landuyt, W
    Verdoes, O
    Darius, DO
    Drijkoningen, M
    Nuyts, S
    Theys, J
    Stockx, L
    Wynendaele, W
    Fowler, JF
    Maleux, G
    Van den Bogaert, W
    Anné, J
    van Oosterom, A
    Lambin, P
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) : 1833 - 1843
  • [39] Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model
    Yeung, Sai-Ching J.
    She, Miaorong
    Yang, Huiling
    Pan, Jingxuan
    Sun, Lily
    Chaplin, David
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08): : 2902 - 2909
  • [40] Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma
    Rojiani, AM
    Li, L
    Rise, L
    Siemann, DW
    ACTA ONCOLOGICA, 2002, 41 (01) : 98 - 105
12345